BRPI0720178A2 - Derivados de 2,3-di-hidroimidazo[1,2-c]quinazolina substituída úteis para tratar distúrbios e doenças hiperproliferativos associados com angiogênese - Google Patents

Derivados de 2,3-di-hidroimidazo[1,2-c]quinazolina substituída úteis para tratar distúrbios e doenças hiperproliferativos associados com angiogênese

Info

Publication number: BRPI0720178A2
Authority: BR; Brazil
Prior art keywords: hydroimidazo; angiogenesis; treat; differences; associated diseases
Prior art date: 2006-12-05

Application number

BRPI0720178-8A2A

Other languages

English (en)

Inventor

Martin Hentemann

Jill Wood

William Scott

Martin Michels

Ann-Marie Campbell

Ann-Marie Bullion

R Bruce Rowley

Aniko Redman

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-05

Filing date

2007-12-05

Publication date

2013-12-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0720178(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-05 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2013-12-24 Publication of BRPI0720178A2 publication Critical patent/BRPI0720178A2/pt

2019-04-09 Publication of BRPI0720178B1 publication Critical patent/BRPI0720178B1/pt

2021-05-25 Publication of BRPI0720178B8 publication Critical patent/BRPI0720178B8/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Environmental Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Dentistry (AREA)
Plant Pathology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Oncology (AREA)
Pulmonology (AREA)
Transplantation (AREA)

BRPI0720178A 2006-12-05 2007-12-05 derivados de 2,3-di-hidroimidazo[1,2-c]quinazolina substituída úteis para tratar distúrbios e doenças hiperproliferativos associados com angiogênese, e composições farmacêuticas BRPI0720178B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US87309006P	2006-12-05	2006-12-05
US60/873,090		2006-12-05
PCT/US2007/024985 WO2008070150A1 (en)	2006-12-05	2007-12-05	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Publications (3)

Publication Number	Publication Date
BRPI0720178A2 true BRPI0720178A2 (pt)	2013-12-24
BRPI0720178B1 BRPI0720178B1 (pt)	2019-04-09
BRPI0720178B8 BRPI0720178B8 (pt)	2021-05-25

Family

ID=39492563

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0720178A BRPI0720178B8 (pt)	2006-12-05	2007-12-05	derivados de 2,3-di-hidroimidazo[1,2-c]quinazolina substituída úteis para tratar distúrbios e doenças hiperproliferativos associados com angiogênese, e composições farmacêuticas

Country Status (41)

Country	Link
US (3)	US8466283B2 (pt)
EP (1)	EP2096919B1 (pt)
JP (1)	JP5326092B2 (pt)
KR (1)	KR101501785B1 (pt)
CN (4)	CN101631464B (pt)
AR (1)	AR064106A1 (pt)
AU (1)	AU2007328008B2 (pt)
BR (1)	BRPI0720178B8 (pt)
CA (1)	CA2671614C (pt)
CL (1)	CL2007003508A1 (pt)
CO (1)	CO6220908A2 (pt)
CR (1)	CR10838A (pt)
CU (1)	CU23796B7 (pt)
DK (1)	DK2096919T3 (pt)
DO (1)	DOP2009000135A (pt)
EA (1)	EA018839B1 (pt)
EC (1)	ECSP099387A (pt)
ES (1)	ES2572189T3 (pt)
GT (1)	GT200900154A (pt)
HN (1)	HN2009001131A (pt)
HU (1)	HUE028773T2 (pt)
IL (1)	IL198273A (pt)
JO (1)	JO3147B1 (pt)
MA (1)	MA31283B1 (pt)
MX (1)	MX2009006001A (pt)
MY (1)	MY157944A (pt)
NO (1)	NO342348B1 (pt)
NZ (1)	NZ577342A (pt)
PA (1)	PA8759601A1 (pt)
PE (1)	PE20081444A1 (pt)
PL (1)	PL2096919T3 (pt)
RS (1)	RS56045B1 (pt)
SG (1)	SG177170A1 (pt)
SI (1)	SI2096919T1 (pt)
SV (1)	SV2009003288A (pt)
TN (1)	TN2009000137A1 (pt)
TW (1)	TWI406662B (pt)
UA (1)	UA96965C2 (pt)
UY (1)	UY30761A1 (pt)
WO (1)	WO2008070150A1 (pt)
ZA (1)	ZA200904691B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8859572B2 (en) *	2008-01-14	2014-10-14	Bayer Intellectual Property Gmbh	Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168583A1 (en)	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en)	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
US8791131B2 (en) *	2008-09-30	2014-07-29	Pfizer Inc.	Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
EP2184276A1 (en)	2008-11-07	2010-05-12	Universite Paul Cezanne Aix-Marseille Iii	Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors
WO2010082627A1 (ja)	2009-01-16	2010-07-22	ダイソー株式会社	２－ヒドロキシメチルモルホリン塩の製造方法
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EA201201414A8 (ru)	2010-04-16	2013-12-30	Байер Интеллектчуал Проперти Гмбх	КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2612669A4 (en)	2010-08-31	2014-05-14	Snu R&Db Foundation	USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
CA2817312A1 (en)	2010-11-11	2012-05-18	Bayer Intellectual Property Gmbh	Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines
UA113280C2 (xx) *	2010-11-11	2017-01-10		АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
WO2012062743A1 (en)	2010-11-11	2012-05-18	Bayer Pharma Aktiengesellschaft	Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
JO3733B1 (ar) *	2011-04-05	2021-01-31	Bayer Ip Gmbh	استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) *	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2861256B1 (en) *	2012-06-15	2019-10-23	The Brigham and Women's Hospital, Inc.	Compositions for treating cancer and methods for making the same
EP2914260A1 (en)	2012-10-31	2015-09-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preventing antiphospholipid syndrome (aps)
KR102185175B1 (ko) *	2012-11-02	2020-12-02	티지 쎄라퓨틱스, 인코포레이티드	항cd20 항체와 pi3 키나아제 선택적 억제제의 조합물
CN103214489B (zh) *	2013-02-25	2016-10-26	中国人民解放军第二军医大学	一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
SG10201710539QA (en)	2013-04-08	2018-01-30	Bayer Pharma AG	Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
CN104557955B (zh) *	2013-10-23	2017-05-03	上海汇伦生命科技有限公司	作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
WO2015081127A2 (en) *	2013-11-26	2015-06-04	Gilead Sciences, Inc.	Therapies for treating myeloproliferative disorders
EP3077003A1 (en)	2013-12-03	2016-10-12	Bayer Pharma Aktiengesellschaft	Combination of pi3k-inhibitors
EP3077002B1 (en) *	2013-12-03	2020-04-22	Bayer Pharma Aktiengesellschaft	Combination of pi3k-inhibitors
TWI533869B (zh)	2014-03-11	2016-05-21	國立中央大學	蒽醌［２，１－ｃ］［１，２，５］噻二唑－６，１１－二酮化合物緩解疼痛的應用
TWI533871B (zh)	2014-03-11	2016-05-21	國立中央大學	萘并［２，３－ｆ］喹喔啉－７，１２－二酮化合物緩解疼痛的應用
FR3018813B1 (fr) *	2014-03-18	2016-04-15	Maco Pharma Sa	Procede de synthese d'un derive de psoralene
WO2016059220A1 (en)	2014-10-16	2016-04-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Tcr-activating agents for use in the treatment of t-all
EP3018131A1 (en)	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en)	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthesis of copanlisib and its dihydrochloride salt
KR20180013851A (ko) *	2015-03-09	2018-02-07	바이엘 파마 악티엔게젤샤프트	치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물
MX2017011607A (es) *	2015-03-09	2018-04-10	Bayer Pharma AG	Uso de 2,3-dihidroimidazol[1,2-c]quinazolinas sustituidas.
FR3033499A1 (fr) *	2015-03-11	2016-09-16	Centre Leon-Berard	Composition pour le traitement des tumeurs neuroendocrines pancreatiques
PL3317284T3 (pl) *	2015-07-02	2020-04-30	F. Hoffmann-La Roche Ag	Związki oksazolidynonu benzoksazepiny i sposoby stosowania
CN105130998B (zh) *	2015-09-25	2017-07-28	苏州立新制药有限公司	库潘尼西的制备方法
CN105130997B (zh) *	2015-09-25	2017-12-05	苏州明锐医药科技有限公司	一种库潘尼西的制备方法
CA3016584A1 (en) *	2016-03-08	2017-09-14	Bayer Pharma Aktiengesellschaft	2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (en)	2016-03-17	2017-09-20	Bayer Pharma Aktiengesellschaft	Combinations of copanlisib
CN115192719B (zh)	2016-05-26	2024-03-01	匹兹堡大学联邦高等教育系统	用于治疗肺血管疾病的组合物和方法
WO2017211248A1 (zh) *	2016-06-08	2017-12-14	深圳市塔吉瑞生物医药有限公司	一种取代的咪唑并喹唑啉化合物及其药物组合物
WO2018054782A1 (en)	2016-09-23	2018-03-29	Bayer Pharma Aktiengesellschaft	Combination of pi3k-inhibitors
CN106177918A (zh) *	2016-09-30	2016-12-07	广州赛莱拉干细胞科技股份有限公司	一种间充质干细胞注射液及其制备方法和应用
US11241500B2 (en)	2016-12-14	2022-02-08	Tarveda Therapeutics, Inc.	HSP90-targeting conjugates and formulations thereof
EP3585437B1 (en)	2017-02-24	2022-12-21	Bayer Pharma Aktiengesellschaft	Combinations of copanlisib with anti-pd-1 antibody
WO2018215282A1 (en)	2017-05-26	2018-11-29	Bayer Pharma Aktiengesellschaft	Combination of bub1 and pi3k inhibitors
US11185549B2 (en)	2017-06-28	2021-11-30	Bayer Consumer Care Ag	Combination of a PI3K-inhibitor with an androgen receptor antagonist
WO2019010491A1 (en) *	2017-07-07	2019-01-10	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
US11344553B2 (en) *	2017-08-11	2022-05-31	Teligene Ltd.	Substituted pyrazolopyrimidines useful as kinases inhibitors
BR112020004545A2 (pt)	2017-09-08	2020-09-08	Bayer Consumer Care Ag	formulações de copanlisib
EP3498266A1 (en)	2017-12-15	2019-06-19	Bayer Consumer Care AG	Formulations of copanlisib
WO2019105734A1 (en)	2017-11-28	2019-06-06	Bayer Consumer Care Ag	Combinations of copanlisib
WO2019105835A1 (en)	2017-11-29	2019-06-06	Bayer Consumer Care Ag	Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en)	2018-04-11	2019-10-17	Bayer Aktiengesellschaft	Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
CN108383849B (zh) *	2018-04-26	2020-11-06	浙江大学	咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用
CN108841318A (zh) *	2018-07-12	2018-11-20	中国科学院海洋研究所	一种自修复壳聚糖水凝胶防腐涂料及其合成方法
EP3843743A1 (en)	2018-08-28	2021-07-07	Bayer AS	Combination of pi3k-inhibitors and targeted thorium conjugates
CA3116230A1 (en)	2018-10-16	2020-04-23	Bayer Aktiengesellschaft	Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CN109516961B (zh) *	2018-12-25	2021-01-01	浙江大学	氨基喹唑啉酮和氨基异喹啉酮衍生物及其应用
WO2020164997A1 (en)	2019-02-12	2020-08-20	Bayer Aktiengesellschaft	Combination of pi3k-inhibitors
WO2023101359A1 (ko) *	2021-11-30	2023-06-08	광주과학기술원	Pip4k2c 억제제를 유효성분으로 포함하는 암 치료용 조성물
WO2023139125A1 (en)	2022-01-18	2023-07-27	Synthon B.V.	Improved process for preparation of copanlisib
WO2023218032A1 (en)	2022-05-13	2023-11-16	Synthon B.V.	Solid forms of copanlisib salts

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3644354A (en)	1968-09-16	1972-02-22	Sandoz Ag	5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4146718A (en)	1978-04-10	1979-03-27	Bristol-Myers Company	Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
JP3729343B2 (ja) *	2000-04-27	2005-12-21	アステラス製薬株式会社	縮合ヘテロアリール誘導体
US6608053B2 (en) *	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
PA8578001A1 (es) *	2002-08-07	2004-05-07	Warner Lambert Co	Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
WO2004029055A1 (en) *	2002-09-30	2004-04-08	Bayer Pharmaceuticals Corporation	Fused azole-pyrimidine derivatives
CA2527533A1 (en) *	2003-06-12	2004-12-29	Merck & Co., Inc.	Mitotic kinesin inhibitors
AT412873B (de)	2004-02-20	2005-08-25	Aop Orphan Pharmaceuticals Ag	Verfahren zur herstellung von anagrelid hydrochlorid
WO2007143483A2 (en)	2006-06-01	2007-12-13	Smithkline Beecham Corporation	Combination of pazopanib and lapatinib for treating cancer
WO2008002039A1 (en)	2006-06-28	2008-01-03	Hanmi Pharm. Co., Ltd.	Quinazoline derivatives for inhibiting the growth of cancer cell
EP2508525A1 (en)	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

2007
- 2007-12-03 AR ARP070105390A patent/AR064106A1/es active IP Right Grant
- 2007-12-04 JO JOP/2007/0517A patent/JO3147B1/ar active
- 2007-12-04 PE PE2007001709A patent/PE20081444A1/es active IP Right Grant
- 2007-12-04 UY UY30761A patent/UY30761A1/es not_active Application Discontinuation
- 2007-12-04 PA PA20078759601A patent/PA8759601A1/es unknown
- 2007-12-04 TW TW096145999A patent/TWI406662B/zh not_active IP Right Cessation
- 2007-12-05 EA EA200900733A patent/EA018839B1/ru not_active IP Right Cessation
- 2007-12-05 NZ NZ577342A patent/NZ577342A/en not_active IP Right Cessation
- 2007-12-05 US US12/517,875 patent/US8466283B2/en not_active Ceased
- 2007-12-05 CN CN200780044849.7A patent/CN101631464B/zh active Active
- 2007-12-05 AU AU2007328008A patent/AU2007328008B2/en not_active Ceased
- 2007-12-05 SI SI200731771A patent/SI2096919T1/sl unknown
- 2007-12-05 CN CN201810535933.9A patent/CN108774232B/zh active Active
- 2007-12-05 CA CA2671614A patent/CA2671614C/en active Active
- 2007-12-05 BR BRPI0720178A patent/BRPI0720178B8/pt not_active IP Right Cessation
- 2007-12-05 SG SG2011088887A patent/SG177170A1/en unknown
- 2007-12-05 MX MX2009006001A patent/MX2009006001A/es active IP Right Grant
- 2007-12-05 MY MYPI20092044A patent/MY157944A/en unknown
- 2007-12-05 ES ES07862580T patent/ES2572189T3/es active Active
- 2007-12-05 KR KR1020097011551A patent/KR101501785B1/ko not_active Expired - Fee Related
- 2007-12-05 EP EP07862580.3A patent/EP2096919B1/en active Active
- 2007-12-05 WO PCT/US2007/024985 patent/WO2008070150A1/en not_active Ceased
- 2007-12-05 HU HUE07862580A patent/HUE028773T2/en unknown
- 2007-12-05 RS RS20170561A patent/RS56045B1/sr unknown
- 2007-12-05 CN CN202211453281.7A patent/CN115724847A/zh active Pending
- 2007-12-05 DK DK07862580.3T patent/DK2096919T3/en active
- 2007-12-05 PL PL07862580T patent/PL2096919T3/pl unknown
- 2007-12-05 CN CN201510632842.3A patent/CN105254634B/zh not_active Expired - Fee Related
- 2007-12-05 CL CL200703508A patent/CL2007003508A1/es unknown
- 2007-12-05 UA UAA200906701A patent/UA96965C2/ru unknown
- 2007-12-05 US US15/398,916 patent/USRE46856E1/en not_active Expired - Fee Related
- 2007-12-05 JP JP2009540293A patent/JP5326092B2/ja not_active Expired - Fee Related
2009
- 2009-04-13 TN TNP2009000137A patent/TN2009000137A1/fr unknown
- 2009-04-21 IL IL198273A patent/IL198273A/en active IP Right Grant
- 2009-06-04 EC EC2009009387A patent/ECSP099387A/es unknown
- 2009-06-04 CO CO09057915A patent/CO6220908A2/es active IP Right Grant
- 2009-06-04 HN HN2009001131A patent/HN2009001131A/es unknown
- 2009-06-05 DO DO2009000135A patent/DOP2009000135A/es unknown
- 2009-06-05 SV SV2009003288A patent/SV2009003288A/es unknown
- 2009-06-05 CU CU20090103A patent/CU23796B7/es active IP Right Grant
- 2009-06-05 GT GT200900154A patent/GT200900154A/es unknown
- 2009-06-05 CR CR10838A patent/CR10838A/es unknown
- 2009-06-29 MA MA32057A patent/MA31283B1/fr unknown
- 2009-07-03 NO NO20092529A patent/NO342348B1/no unknown
- 2009-07-03 ZA ZA200904691A patent/ZA200904691B/xx unknown
2013
- 2013-06-03 US US13/908,566 patent/US20130261113A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SG177170A1 (en)	2012-01-30
EP2096919A1 (en)	2009-09-09
TN2009000137A1 (en)	2010-10-18
ES2572189T3 (es)	2016-05-30
BRPI0720178B8 (pt)	2021-05-25
DOP2009000135A (es)	2009-06-30
US8466283B2 (en)	2013-06-18
MA31283B1 (fr)	2010-04-01
JO3147B1 (ar)	2017-09-20
ECSP099387A (es)	2009-11-30
ZA200904691B (en)	2010-09-29
US20110083984A1 (en)	2011-04-14
RS56045B1 (sr)	2017-09-29
SI2096919T1 (sl)	2016-06-30
BRPI0720178B1 (pt)	2019-04-09
UY30761A1 (es)	2008-07-03
NZ577342A (en)	2012-01-12
NO342348B1 (no)	2018-05-07
MY157944A (en)	2016-08-30
USRE46856E1 (en)	2018-05-22
EA018839B1 (ru)	2013-11-29
GT200900154A (es)	2012-01-17
NO20092529L (no)	2009-08-27
PL2096919T3 (pl)	2016-08-31
CO6220908A2 (es)	2010-11-19
AR064106A1 (es)	2009-03-11
MX2009006001A (es)	2009-06-16
IL198273A0 (en)	2009-12-24
CA2671614A1 (en)	2008-06-12
CN108774232A (zh)	2018-11-09
CN101631464A (zh)	2010-01-20
HN2009001131A (es)	2012-02-06
US20130261113A1 (en)	2013-10-03
WO2008070150A1 (en)	2008-06-12
CN108774232B (zh)	2022-08-09
CN105254634A (zh)	2016-01-20
CN105254634B (zh)	2022-05-27
UA96965C2 (ru)	2011-12-26
KR101501785B1 (ko)	2015-03-11
HUE028773T2 (en)	2017-01-30
CA2671614C (en)	2016-01-26
JP5326092B2 (ja)	2013-10-30
EA200900733A1 (ru)	2009-12-30
KR20090096440A (ko)	2009-09-10
CR10838A (es)	2009-11-05
PA8759601A1 (es)	2009-02-09
CN101631464B (zh)	2022-12-06
CU20090103A7 (es)	2011-12-28
CU23796B7 (es)	2012-03-15
TW200840582A (en)	2008-10-16
DK2096919T3 (en)	2016-05-17
TWI406662B (zh)	2013-09-01
AU2007328008B2 (en)	2014-03-13
PE20081444A1 (es)	2008-11-29
IL198273A (en)	2015-07-30
HK1217953A1 (zh)	2017-01-27
JP2010511718A (ja)	2010-04-15
SV2009003288A (es)	2009-10-02
EP2096919B1 (en)	2016-03-02
EP2096919A4 (en)	2010-11-17
AU2007328008A1 (en)	2008-06-12
CL2007003508A1 (es)	2008-07-04
CN115724847A (zh)	2023-03-03

Legal Events

Date	Code	Title	Description
2014-04-15	B25D	Requested change of name of applicant approved	Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)
2014-05-06	B25A	Requested transfer of rights approved	Owner name: BAYER INTELLECTUAL PROPERTY GMBH. (DE)
2018-03-20	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2018-03-20	B65X	Notification of requirement for priority examination of patent application
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-02	B65Y	Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
2018-11-06	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2018-11-13	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-02-26	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-04-09	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-04-02	B25G	Requested change of headquarter approved	Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)
2025-10-07	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 18A ANUIDADE.
2026-01-27	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2857 DE 07-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0720178A2 (pt)	2013-12-24	Derivados de 2,3-di-hidroimidazo[1,2-c]quinazolina substituída úteis para tratar distúrbios e doenças hiperproliferativos associados com angiogênese
SMT201500206B (it)	2015-10-30	Composti spiro-ossindolici e loro uso come agenti terapeutici
PL1881823T3 (pl)	2015-05-29	Kompozycje i sposoby leczenia chorób oczu
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
ATE467633T1 (de)	2010-05-15	2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
BRPI0716844A2 (pt)	2013-10-22	Inidores de quinase úteis para o tratamento de doenças proliferativas
SI3424932T1 (sl)	2021-08-31	Boronoftalidi za terapevtsko uporabo
SI2084151T1 (sl)	2013-10-30	Substituirani dihidropirazoloni za zdravljenje kardiovaskularnih in hematoloĹˇkih bolezni
ECSP088904A (es)	2008-12-30	Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
BRPI0812755A2 (pt)	2014-09-30	Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
BR112012001344A2 (pt)	2016-03-15	derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
CL2007002837A1 (es)	2008-07-18	Uso de fenitoina para tratar mucositis oral.
SI2176252T1 (sl)	2014-12-31	2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
PL2049127T3 (pl)	2015-03-31	N-metanokarbapochodne do leczenia chorób serca
BRPI0718041A2 (pt)	2015-05-12	Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos
BRPI0908049A2 (pt)	2015-08-11	Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr
DK1993589T3 (da)	2014-01-06	Behandlinger for neurologiske sygdomme
PL2307000T3 (pl)	2014-09-30	Połączenie pilokarpiny i metimazolu do leczenia choroby Charcota-Mariegotootha i pokrewnych zaburzeń
EP2049899A4 (en)	2010-04-14	METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES
PT2056804E (pt)	2014-07-11	Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
EP1863899A4 (en)	2009-12-30	COMPOSITIONS FOR TREATING SKIN
FI20095600L (fi)	2009-06-09	Koostumus ihosairauksien hoitoa varten
BRPI0818121A2 (pt)	2015-11-17	diespiro 1,2,4-trioxolano e seus métodos de fabricação e utilização
BRPI0822223A2 (pt)	2015-06-23	Derivados de imidazo [1,2-alfa] piridina-2-carboxamidas, sua preparação e sua aplicação em terapêutica
ZA200810565B (en)	2009-11-25	Pyrimidine derivatives and their use as pesticides